Calculation of Direct Antiretroviral Treatment Costs and Potential Cost Savings by Using Generics in the German HIV ClinSurv Cohort

Background/Aim of the Study The study aimed to determine the cost impacts of antiretroviral drugs by analysing a long-term follow-up of direct costs for combined antiretroviral therapy, cART,-regimens in the nationwide long-term observational multi-centre German HIV ClinSurv Cohort. The second aim was to develop potential cost saving strategies by modelling different treatment scenarios. Methods Antiretroviral regimens (ART) from 10,190 HIV-infected patients from 11 participating ClinSurv study centres have been investigated since 1996. Biannual data cART,-initiation, cART-changes, surrogate markers, clinical events and the Centre of Disease Control- (CDC)-stage of HIV disease are reported. Treatment duration was calculated on a daily basis via the documented dates for the beginning and end of each antiretroviral drug treatment. Prices were calculated for each individual regimen based on actual office sales prices of the branded pharmaceuticals distributed by the license holder including German taxes. Results During the 13-year follow-up period, 21,387,427 treatment days were covered. Cumulative direct costs for antiretroviral drugs of €812,877,356 were determined according to an average of €42.08 per day (€7.52 to € 217.70). Since cART is widely used in Germany, the costs for an entire regimen increased by 13.5%. Regimens are more expensive in the advanced stages of HIV disease. The potential for cost savings was calculated using non-nucleotide-reverse-transcriptase-inhibitor, NNRTI, more frequently instead of ritonavir-boosted protease inhibitor, PI/r, in first line therapy. This calculation revealed cumulative savings of 10.9% to 19.8% of daily treatment costs (50% and 90% substitution of PI/r, respectively). Substituting certain branded drugs by generic drugs showed potential cost savings of between 1.6% and 31.8%. Conclusions Analysis of the data of this nationwide study reflects disease-specific health services research and will give insights into the cost impacts of antiretroviral therapy, and might allow a more rational allocation of resources within the German health care system.

[1]  M. Battegay,et al.  Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study * , 2011, HIV medicine.

[2]  D. Matysiak-Klose,et al.  Cohort profile: the German ClinSurv HIV project – a multicentre open clinical cohort study supplementing national HIV surveillance , 2011, HIV medicine.

[3]  M. Gilliam.  Pharmaceutical Policies: Effects of Restrictions on Reimbursement , 2011, Obstetrics and gynecology.

[4]  M. Stoll,et al.  PIN75 ESTIMATION OF PATIENTS WITH ANTIRETROVIRAL THERAPY POTENTIALLY USED FOR HIV PREVENTION (POST-EXPOSURE PROPHYLAXIS, MOTHER-TO-CHILD TRANSMISSION PROPHYLAXIS) IN GERMANY , 2010 .

[5]  C. Ramsay,et al.  Pharmaceutical policies: effects of restrictions on reimbursement. , 2010, The Cochrane database of systematic reviews.

[6]  J. Schapiro,et al.  Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[7]  B. Gazzard,et al.  The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study. , 2010, Antiviral research.

[8]  K. Metzner,et al.  Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. , 2010, The Journal of infectious diseases.

[9]  S. Tazuma,et al.  Comparing the Acid-Suppressive Effects of Three Brands of Generic Lansoprazole with the Original: Pharmacokinetic Bioequivalence Tests Do Not Necessarily Guarantee Pharmacodynamic Equivalence , 2009, Digestive Diseases and Sciences.

[10]  H. Leufkens,et al.  Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases. , 2009, Bulletin of the World Health Organization.

[11]  J. Liberman,et al.  Impact of pharmacy benefit design on prescription drug utilization: a fixed effects analysis of plan sponsor data. , 2009, Health services research.

[12]  J. Wasem,et al.  Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach. , 2009, Health economics.

[13]  R. Zeckhauser,et al.  Generic script share and the price of brand-name drugs: the role of consumer choice , 2009, International Journal of Health Care Finance and Economics.

[14]  J. Mellors,et al.  Simplification Strategies to Reduce Antiretroviral drug Exposure: Progress and Prospects , 2009, Antiviral therapy.

[15]  Ross J. Harris,et al.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies , 2008, The Lancet.

[16]  R. Busse,et al.  Pricing behaviour of pharmacies after market deregulation for OTC drugs: the case of Germany. , 2007, Health policy.

[17]  N. Parkin,et al.  A Comparison of the Phenotypic Susceptibility Profiles of Emtricitabine and Lamivudine , 2007, Antiviral chemistry & chemotherapy.

[18]  Milton C Weinstein,et al.  The survival benefits of AIDS treatment in the United States. , 2006, The Journal of infectious diseases.

[19]  A. Levy,et al.  The direct costs of HIV/AIDS care. , 2006, Lancet. Infectious Diseases (Print).

[20]  J. Schulenburg.  German health care system in transition , 2005, The European Journal of Health Economics.

[21]  K. Borroto-Esoda,et al.  In Vitro Evaluation of the Anti-HIV Activity and Metabolic Interactions of Tenofovir and Emtricitabine , 2005, Antiviral therapy.

[22]  A. Wu,et al.  Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence , 2005, AIDS care.

[23]  N. Rudholm,et al.  Side effects of generic competition? , 2004, The European Journal of Health Economics, formerly: HEPAC.

[24]  J. Graf von der Schulenburg,et al.  Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. , 2002, European journal of medical research.

[25]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[26]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[27]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[28]  J. Wheeler,et al.  Government regulation of pricing and reimbursement of prescription medicines: results of a recent multi-country review. , 2009, Food and drug law journal.

[29]  J. G. von der Schulenburg.  German health care system in transition. The difficult way to balance cost containment and solidarity. , 2005, The European journal of health economics : HEPAC : health economics in prevention and care.